Empatab25 mg

Empatab 25 mg is an oral antidiabetic medicine belonging to the sodium-glucose co-transporter-2 (SGLT2) inhibitor class. It is prescribed for the following conditions:

• Type 2 diabetes mellitus: As an adjunct to diet and exercise to improve glycemic control (blood sugar management) in adults.
• Cardiovascular risk reduction: To reduce the risk of cardiovascular death in adult patients who have both type 2 diabetes mellitus and established cardiovascular disease.

Empatab 25 mg works independently of insulin, helping the kidneys remove excess glucose through the urine. It is often used alone or in combination with other antidiabetic agents such as metformin, insulin, or DPP-4 inhibitors to achieve target blood sugar levels.

Always take this medicine according to the advice of a registered physician.

Empatab 25 mg belongs to the Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors class of antidiabetic medicines.

Empatab 25 mg is a potent and selective inhibitor of the sodium-glucose co-transporter-2 (SGLT2), the primary transporter responsible for reabsorbing glucose from the glomerular filtrate back into the bloodstream in the proximal renal tubule.

By blocking SGLT2, Empatab 25 mg lowers the renal threshold for glucose and reduces the reabsorption of filtered glucose. This increases urinary glucose excretion (glucuresis), leading to reduced blood glucose levels. Because this mechanism is insulin-independent, the risk of hypoglycemia is low when Empatab 25 mg is used on its own.

Beyond glycemic control, the loss of glucose (and its associated calories) through urine contributes to modest weight reduction. The accompanying mild osmotic diuresis and natriuresis also help lower blood pressure, which supports its cardiovascular protective benefits.

Empatab 25 mg may interact with certain medicines and laboratory tests. The following interactions are clinically relevant:

• Diuretics: Taking Empatab 25 mg with diuretics can increase urine output and the risk of dehydration and low blood pressure.
• Insulin or insulin secretagogues: Combining Empatab 25 mg with insulin or sulfonylureas raises the risk of hypoglycemia. A dose reduction of insulin or the secretagogue may be required.
• Urine glucose tests: Because SGLT2 inhibitors increase urinary glucose excretion, urine glucose tests will read positive. These tests are not reliable for monitoring glycemic control; alternative methods should be used.
• 1,5-anhydroglucitol (1,5-AG) assay: Measurements from this assay are unreliable in patients taking SGLT2 inhibitors and should not be used to assess blood sugar control.

Inform your doctor about all prescription medicines, over-the-counter drugs, and supplements you are taking before starting Empatab 25 mg.

Like all medicines, Empatab 25 mg can cause side effects, although not everyone experiences them. The most commonly reported adverse reactions include:

• Urinary tract infections (UTIs).
• Female genital mycotic (fungal) infections, such as vaginal thrush.
• Dehydration due to increased urination.
• Low blood pressure (hypotension), which may cause dizziness or fainting.
• Weakness and fatigue.
• Dizziness.
• Increased thirst.

Genital fungal infections may also affect males. Maintaining good personal hygiene and drinking adequate fluids can help reduce the risk. Seek medical attention promptly if you experience severe or persistent side effects.

Pregnancy: There are no adequate and well-controlled studies of Empatab 25 mg in pregnant women. It should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus. Use is generally not recommended, particularly during the second and third trimesters.

Lactation: It is not known whether Empatab 25 mg passes into human breast milk. Because of the potential risk to the nursing infant, Empatab 25 mg is not recommended while breastfeeding.

Women who are pregnant, planning to become pregnant, or breastfeeding should consult their doctor before using this medicine.

The following precautions should be observed while using Empatab 25 mg:

• Kidney function: Assessment of renal function is recommended before starting treatment and periodically thereafter. Empatab 25 mg should not be initiated in patients with an eGFR below 45 mL/min/1.73 m². No dose adjustment is needed for patients with an eGFR of 45 mL/min/1.73 m² or higher.
• Volume depletion: Empatab 25 mg can cause fluid loss. Patients who are elderly, on diuretics, or have low blood pressure should be monitored closely and kept well hydrated.
• Ketoacidosis: Watch for symptoms of diabetic ketoacidosis (nausea, vomiting, abdominal pain, difficulty breathing) and seek immediate care if they occur, even if blood sugar is not very high.
• Genital and urinary infections: Practice good hygiene to lower the risk of fungal and urinary tract infections.
• Hypoglycemia: The risk increases when combined with insulin or insulin secretagogues.

Report any signs of dizziness, persistent joint pain, cold-like symptoms, or unexplained nausea and vomiting to your doctor.

In the event of an overdose with Empatab 25 mg, standard supportive measures should be taken based on the patient's clinical status. This may include removing any unabsorbed medicine from the gastrointestinal tract, performing clinical monitoring, and providing supportive treatment as needed.

The removal of Empatab 25 mg by hemodialysis has not been studied. If an overdose is suspected, seek emergency medical assistance immediately.

Keep Empatab 25 mg in a cool and dry place, below 30°C, protected from light and moisture. Store the medicine in its original packaging and keep it out of the reach of children. Do not use the tablets after the expiry date printed on the packaging.

Renal impairment: Empatab 25 mg should not be started in patients with an eGFR below 45 mL/min/1.73 m². Its glucose-lowering effectiveness depends on kidney function and diminishes as renal function declines. It is contraindicated in severe renal impairment, end-stage renal disease, and dialysis.

Hepatic impairment: No dose adjustment is required for patients with mild to moderate liver disease. Use in severe hepatic impairment should be guided by a physician.

Elderly patients: Older adults may be more susceptible to volume depletion and its effects. Careful monitoring of hydration status and blood pressure is advised.

Pediatric use: The safety and effectiveness of Empatab 25 mg in children and adolescents have not been established for all indications.

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Empatab 25 mg is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.

There are no adequate and well-controlled studies of Empatab 25 mg in pregnant women. Empatab 25 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Empatab 25 mg is excreted in human milk. It is not recommended when breastfeeding.